Journal of Clinical Gynecology and Obstetrics, ISSN 1927-1271 print, 1927-128X online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Gynecol Obstet and Elmer Press Inc
Journal website https://jcgo.elmerpub.com

Short Communication

Volume 000, Number 000, October 2025, pages 000-000


Intrapartum Terbutaline Use and Cesarean Delivery for Labor Dystocia

Tables

Table 1. Baseline Characteristics
 
No terbutaline (n = 683)Received terbutaline (n = 161)P-value
All data presented as n (%) unless otherwise noted. aMedian (IQR). IOL: induction of labor; IQR: interquartile range; NRFHT: non-reassuring fetal heart tracing.
Agea28.2 (23.8 - 33.2)27.9 (22.6 - 32.5)0.24
Body mass index (kg/m2)a32.7 (28.1 - 37.6)33.1 (29.2 - 39.0)0.09
Nulliparous423 (61.9)112 (69.6)0.07
Race0.59
  White138 (20.2)27 (16.8)
  Black488 (71.4)121 (75.2)
  Other57 (8.3)13 (8.1)
Ethnicity0.48
  Non-Hispanic661 (96.8)154 (95.7)
  Hispanic22 (3.2)7 (4.3)
Gestational or pre-gestational diabetes38 (5.5)12 (7.4)0.35
Chronic hypertension53 (7.8)6 (3.7)0.07
Pregnancy related hypertension228 (32.9)58 (35.8)0.48
Indication for IOL0.65
  Post-dates105 (15.4)24 (14.9)
  Maternal indication190 (27.8)45 (28.0)
  Fetal indication306 (44.8)78 (48.4)
  Elective/other82 (12.0)14 (8.7)
Gestational age at deliverya39.3 (38.1 - 40.6)39.4 (38.4 - 40.6)0.52
Initial cervical dilationa1.0 (1.0 - 1.5)1.0 (0.5 - 1.5)<0.01
Initial Bishop score3 (2, 5)3 (2, 5)0.08

 

Table 2. Delivery Outcomes
 
No terbutaline (n = 683)Received terbutaline (n = 161)P-value
All data presented as n (%) unless otherwise noted. aMedian (IQR). bP-value among doses 0.31. cTime from initiation of induction to delivery of the neonate regardless of ultimate mode of delivery. IQR: interquartile range; NRFHT: non-reassuring fetal heart tracing.
Cesarean delivery162 (24)82 (51)< 0.001
Cesarean for NRFHT29 (4.2)42 (26.1)< 0.001
Cesarean for labor dystocia133 (19.5)40 (24.8)0.13
Number of doses of terbutaline-1 dose: 21 (22.3)
2 doses: 13 (26.5)
> 3 doses: 6 (33.3)b
0.31
Latent phase (h)a10.4 (7.2 - 15.1)11.8 (7.9 - 17.7)0.02
Active phase (h)a2.3 (0.5 - 5.2)2.5 (0.0 - 5.9)0.66
Second stage (h)a0.5 (0.2 - 1.3)0.6 (0.2 - 1.3)0.47
Length of labor (h)a, c16.2 (10.8 - 23.2)18.3 (14.1 - 25.8)< 0.01